Pliant Therapeutics, Inc. (NASDAQ:PLRX) Stock Rated “Hold” by Wall Street Brokerages

Pliant Therapeutics, Inc. (NASDAQ:PLRX) has received an average rating of “Hold” from the three research firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and one has assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $3.00.

A number of research firms have recently commented on PLRX. Weiss Ratings reissued a “sell (e+)” rating on shares of Pliant Therapeutics in a research note on Friday, July 17th. Wall Street Zen upgraded Pliant Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 26th.

Pliant Therapeutics Price Performance

Shares of NASDAQ:PLRX opened at $0.97 on Wednesday. Pliant Therapeutics has a 12 month low of $0.96 and a 12 month high of $1.95. The stock’s 50 day moving average price is $1.10 and its 200 day moving average price is $1.16.

Pliant Therapeutics (NASDAQ:PLRX) last released its earnings results on Tuesday, August 11th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.02). Research analysts forecast that Pliant Therapeutics will post -1.42 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. ADAR1 Capital Management LLC acquired a new position in shares of Pliant Therapeutics in the 2nd quarter worth approximately $6,281,000. Monaco Asset Management SAM bought a new stake in shares of Pliant Therapeutics in the 2nd quarter worth approximately $2,210,000. Renaissance Technologies LLC raised its holdings in shares of Pliant Therapeutics by 77.2% in the 1st quarter. Renaissance Technologies LLC now owns 1,852,842 shares of the company’s stock worth $2,335,000 after purchasing an additional 807,024 shares in the last quarter. BlackRock Inc. acquired a new stake in Pliant Therapeutics during the second quarter valued at approximately $1,312,000. Finally, Eversept Partners LP lifted its stake in Pliant Therapeutics by 5.9% during the first quarter. Eversept Partners LP now owns 891,425 shares of the company’s stock valued at $1,123,000 after purchasing an additional 49,402 shares during the last quarter. 97.30% of the stock is owned by institutional investors and hedge funds.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for fibrotic diseases. The company uses its expertise in integrin biology to discover and develop medicines intended to address the underlying mechanisms that contribute to tissue scarring and organ dysfunction.

Pliant’s leading investigational product is bexotegrast, an oral, small-molecule inhibitor designed to selectively target the alphaVbeta6 and alphaVbeta1 integrins. The therapy has been studied in conditions including idiopathic pulmonary fibrosis, a progressive lung disease, and primary sclerosing cholangitis, a chronic liver disease.